Pioneering Smarter Heart Health With Purpose and Precision
At HeartForce™, we’re dedicated to revolutionizing coronary artery disease (CAD) detection by enabling early and precise risk screening that is more effective, accessible, and easier to administer at all levels of healthcare.
Behind this mission stands a passionate, interdisciplinary team of physicians, engineers, data scientists, medtech industry experts, and entrepreneurs. Together, we are reshaping the potential of cardiovascular prevention through science, empathy, and innovation.
From our early roots to our latest clinical successes, our journey is guided by one mission: helping people live longer, healthier lives.
Our Founder's Story
Beat Nägeli
Founder & Shareholder at HeartForce AG
In 2008, I experienced a heart attack unexpectedly despite regular check-ups, good health and no symptoms of coronary artery disease.
It shocked me, my family, and close friends. Thankfully, I survived.
Sadly, 30% of the people who suffer a heart attack, do not. Coronary artery disease remains the number one silent killer, globally.
We started HeartForce to make heart disease a concern of the past and to ensure that our loved ones never again leave us too soon.
On behalf of HeartForce, I hope you will join us on this worthwhile journey.
Beat Nägeli
Founder & Shareholder at Heart Force AG
Phase 1
Beginnings in Canada (2004–2010)
Founding
Heart Force Medical Inc. was founded in Vancouver, BC.
Invention of dbg-300
Developed the idea for a digital ballistocardiograph and invented the dbg-300.
BC Tech Award
Won the BC Technology Impact Association Award.
U.S. FDA Approval
Received U.S. FDA approval for the dbg-300.
CE Mark Approval
Phase 2
Transition to Europe & Focus (2015–2018)
Heart Force AG Founded
Core Scientific Studies
Phase 3
Product & Global Expansion (2019–2022)
Cardio Pro Developed
Developed the product Cardio Pro, a self-monitoring heart screening device.
Asian Market Entry
Took fifth place in the K-Startup Grand Challenge in South Korea, opening up the Asian market.
Cardio Clin 2.0
Collected data in Uzbekistan, improved algorithms, and presented improved versions of the Cardio Clin 2.0.
Phase 4
EMCR-Score & Platform Development (2023–2024)
EMCR-Score Finalized
Finalized the algorithm for the Electro-mechanical CAD Risk Score (EMCR-Score) and developed an algorithm to detect Afib.
CardioClin 3.0
Developed the CardioClin 3.0 platform, integrated the EMR score, and received the hardware design freeze.
Phase 5
Current Developments (Until End of 2025)
Final Device & App Alpha
Final Cardio Clin version produced; alpha version of the mobile app tested.
FDA Pre-Submission
Achieved FDA pre-submission.
Usability Testing
Start of usability testing.
About HeartForce
Heart Force originated in Canada in 2004 and developed the digital ballistocardiograph, a portable device that measures the opening and closing of heart valves using acceleration sensors.
Following initial FDA and CE approvals and patenting, the company was restructured, which led to the creation of Heart Force AG as the parent company.
Since 2019, Heart Force has focused on the CardioClin™ platform and the “Electro-mechanical CAD Risk Score,” which aims to detect coronary artery disease quickly, accurately, and cost-effectively.
The most recent milestones include the completion of the CardioClin 3.0 device generation, the preparation for regulatory approvals (Health Canada, FDA and CE mark) and the expansion of global marketing.
News & Updates
Contact Us
Explore Partnerships
Looking to improve patient outcomes and reduce unnecessary testing with a scalable, cost-effective, and patient-friendly CAD screening solution?